nach oben

Erschienen in:

30.05.2017 | Topic Review

Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations

verfasst von: Charles A. Kunos, Evanthia Galanis, Jeffrey Buchsbaum, Qian Shi, Lewis C. Strauss, C. Norman Coleman, Mansoor M. Ahmed

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation–chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation–investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.

Jacks T, Jaffee E, Singer D (2016) Cancer Moonshot Blue Ribbon Panel Report 2016. National Cancer Advisory Board. http://www.cancer.gov/brp. Accessed 4 Jan 2017

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 17(Suppl 4):iv1–iv62. doi:10.1093/neuonc/nov189 CrossRefPubMedPubMedCentral

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR et al (2013) The somatic genomic landscape of glioblastoma. Cell 155(2):462–477. doi:10.1016/j.cell.2013.09.034 CrossRefPubMedPubMedCentral

Osorio JA, Aghi MK (2014) Optimizing glioblastoma resection: intraoperative mapping and beyond. CNS Oncol 3(5):359–366. doi:10.2217/cns.14.36 CrossRefPubMed

Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7(5):392–401. doi:10.1016/s1470-2045(06)70665-9 CrossRefPubMed

Jue TR, McDonald KL (2016) The challenges associated with molecular targeted therapies for glioblastoma. J Neurooncol 127(3):427–434. doi:10.1007/s11060-016-2080-6 CrossRefPubMed

Platten M, Bunse L, Wick W, Bunse T (2016) Concepts in glioma immunotherapy. Cancer Immunol Immunother 65(10):1269–1275. doi:10.1007/s00262-016-1874-x CrossRefPubMed

Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4(4):296–307. doi:10.1038/nrc1319 CrossRefPubMed

Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22(4):425–437. doi:10.1016/j.ccr.2012.08.024 CrossRefPubMed

10.

Levin VA, Wilson CB, Davis R, Wara WM, Pischer TL, Irwin L (1979) A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. J Neurosurg 51(4):526–532. doi:10.3171/jns.1979.51.4.0526 CrossRefPubMed

11.

Gutin PH, Wilson CB, Kumar AR, Boldrey EB, Levin V, Powell M, Enot KJ (1975) Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer 35(5):1398–1404CrossRefPubMed

12.

Tang JB, Svilar D, Trivedi RN, Wang XH, Goellner EM, Moore B et al (2011) N-Methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. Neuro Oncol 13(5):471–486. doi:10.1093/neuonc/nor011 CrossRefPubMedPubMedCentral

13.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330 CrossRefPubMed

14.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):97–1003. doi:10.1056/NEJMoa043331 CrossRef

15.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708. doi:10.1056/NEJMoa1308573 CrossRefPubMedPubMedCentral

16.

Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722. doi:10.1056/NEJMoa1308345 CrossRefPubMed

17.

Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL (1999) Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res 5(10):2908–2917PubMed

18.

Taverna P, Liu L, Hwang HS, Hanson AJ, Kinsella TJ, Gerson SL (2001) Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat Res 485(4):269–281CrossRefPubMed

19.

Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D et al (2007) Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 13(24):7401–7406. doi:10.1158/1078-0432.ccr-07-0781 CrossRefPubMedPubMedCentral

20.

Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ et al (2016) Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clin Cancer Res. doi:10.1158/1078-0432.ccr-15-3153 PubMedCentral

21.

Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH et al (2008) Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26(34):5603–5609. doi:10.1200/jco.2008.18.0612 CrossRefPubMedPubMedCentral

22.

Ma DJ, Galanis E, Anderson SK, Schiff D, Kaufmann TJ, Peller PJ et al (2015) A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol 17(9):1261–1269. doi:10.1093/neuonc/nou328 CrossRefPubMed

23.

Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Easaw JC, Macdonald DR et al (2015) Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol 17(9):1270–1274. doi:10.1093/neuonc/nou365 PubMedPubMedCentral

24.

Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN (2002) Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62(24):7291–7297PubMed

25.

Guo Y, Kwiatkowski DJ (2013) Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis. Mol Cancer Res 11(5):467–473. doi:10.1158/1541-7786.mcr-12-0605 CrossRefPubMedPubMedCentral

26.

Canon J, Osgood T, Olson SH, Saiki AY, Robertson R, Yu D et al (2015) The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents. Mol Cancer Ther 14(3):649–658. doi:10.1158/1535-7163.mct-14-0710 CrossRefPubMed

27.

Werner LR, Huang S, Francis DM, Armstrong EA, Ma F, Li C et al (2015) Small molecule inhibition of MDM2-p53 interaction augments radiation response in human tumors. Mol Cancer Ther 14(9):1994–2003. doi:10.1158/1535-7163.mct-14-1056-t CrossRefPubMed

28.

Lambiv WL, Vassallo I, Delorenzi M, Shay T, Diserens AC, Misra A et al (2011) The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol 13(7):736–747. doi:10.1093/neuonc/nor036 CrossRefPubMedPubMedCentral

29.

Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E et al (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3(11):1427–1438PubMed

30.

Furgason JM, Koncar RF, Michelhaugh SK, Sarkar FH, Mittal S, Sloan AE et al (2015) Whole genome sequence analysis links chromothripsis to EGFR, MDM2, MDM4, and CDK4 amplification in glioblastoma. Oncoscience 2(7):618–628. doi:10.18632/oncoscience.178 CrossRefPubMedPubMedCentral

31.

Veeravagu A, Hou LC, Hsu AR, Cai W, Greve JM, Chen X, Tse V (2008) The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model. Neurol Res 30(9):952–959. doi:10.1179/174313208x322761 CrossRefPubMed

32.

de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 12(3):233–242. doi:10.1093/neuonc/nop027 CrossRefPubMedPubMedCentral

33.

Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745. doi:10.1200/jco.2008.16.3055 CrossRefPubMed

34.

Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK et al (2013) Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 19(17):4816–4823. doi:10.1158/1078-0432.ccr-13-0708 CrossRefPubMed

35.

Hainsworth JD, Ervin T, Friedman E, Priego V, Murphy PB, Clark BL, Lamar RE (2010) Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 116(15):3663–3669. doi:10.1002/cncr.25275 CrossRefPubMed

36.

Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A et al (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31(26):3212–3218. doi:10.1200/jco.2012.47.2464 CrossRefPubMedPubMedCentral

37.

Hutterer M, Nowosielski M, Haybaeck J, Embacher S, Stockhammer F, Gotwald T et al (2014) A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01–07). Neuro Oncol 16(1):92–102. doi:10.1093/neuonc/not161 CrossRefPubMed

38.

Chen W, Tang T, Eastham-Anderson J, Dunlap D, Alicke B, Nannini M et al (2011) Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells. Proc Natl Acad Sci USA 108(23):9589–9594. doi:10.1073/pnas.1017945108 CrossRefPubMedPubMedCentral

39.

Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I et al (2015) Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J Clin Oncol 33(24):2646–2654. doi:10.1200/jco.2014.60.1591 CrossRefPubMedPubMedCentral

40.

Chandra V, Das T, Gulati P, Biswas NK, Rote S, Chatterjee U et al (2015) Hedgehog signaling pathway is active in GBM with GLI1 mRNA expression showing a single continuous distribution rather than discrete high/low clusters. PLoS ONE 10(3):e0116390. doi:10.1371/journal.pone.0116390 CrossRefPubMedPubMedCentral

41.

Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A et al (2015) Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 17(8):1064–1075. doi:10.1093/neuonc/nou307 CrossRefPubMed

42.

Zhang HH, Molitoris JK, Tan S, Giacomelli I, Scartoni D, Gzell C et al (2016) Radiomics for survival analysis and prediction in glioblastoma (GBM)—a preliminary study. Int J Radiat Oncol Biol Phys 96(2S):E106–E107. doi:10.1016/j.ijrobp.2016.06.860

43.

Qutub MA, Klein SB, Buchsbaum JC (2015) Rapid RBE-weighted proton radiation dosimetry risk assessment. Technol Cancer Res Treat 15(5):NP1–NP7. doi:10.1177/1533034615599313 CrossRefPubMed

44.

Prasanna A, Ahmed MM, Mohiuddin M, Coleman CN (2014) Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy. J Thorac Dis 6(4):287–302. doi:10.3978/j.issn.2072-1439.2014.01.14 PubMedPubMedCentral

45.

Kovacs A, Emri M, Opposits G, Pisak T, Vandulek C, Glavak C et al (2015) Changes in functional MRI signals after 3D based radiotherapy of glioblastoma multiforme. J Neuro Oncol 125(1):157–166. doi:10.1007/s11060-015-1882-2 CrossRef

46.

Simon R, Maitournam A (2004) Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 10(20):6759–6763. doi:10.1158/1078-0432.ccr-04-0496 CrossRefPubMed

47.

Maitournam A, Simon R (2005) On the efficiency of targeted clinical trials. Stat Med 24(3):329–339. doi:10.1002/sim.1975 CrossRefPubMed

48.

Simon R, Wittes RE, Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69(12):1375–1381PubMed

49.

Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA (2005) Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 23(28):7199–7206. doi:10.1200/jco.2005.01.149 CrossRefPubMed

50.

U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (2010) Guidance for industry: adaptive design clinical trials for drugs and biologics. Food and Drug Administration, Silver Spring. http://www.fda.gov/downloads/drugs/guidances/ucm201790.pdf. Accessed 4 Jan 2017

51.

Walker AJ, Kim H, Saber H, Kim G, Kleutz P, Pazdur R (2017). Clinical development of cancer drugs in combination with external beam radiation therapy: FDA perspective. Int J Radiat Oncol Biol Phys 98(1):5–7

Titel: Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations
verfasst von: Charles A. Kunos
Evanthia Galanis
Jeffrey Buchsbaum
Qian Shi
Lewis C. Strauss
C. Norman Coleman
Mansoor M. Ahmed
Publikationsdatum: 30.05.2017
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2017
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2458-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

GBM radiosensitizers: dead in the water…or just the beginning?

The role of radiation in treating glioblastoma: here to stay

Management of GBM: a problem of local recurrence

Pediatric high-grade glioma: current molecular landscape and therapeutic approaches

The evolving role for re-irradiation in the management of recurrent grade 4 glioma

Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie